A programme for long-term retention studies of 14C-labelled compounds in man using the Lund AMS facility
Organic compounds labelled with 14C are routinely and widely used in clinical medicine and biomedical research. There are, however, considerable uncertainties in the current estimates of the absorbed doses to the body from 14C-labelled radiopharmaceuticals. In this paper a project is described using accelerator mass spectrometry (AMS) to perform investigations of the long-term biokinetics of 14C from various 14C-labelled pharmaceuticals in man. The use of the AMS technique makes it possible to follow the turnover of the radionuclide administered for extensive periods and also to decrease the activity administered.